Cutaneous Amyloidosis Associated with Amyopathic Dermatomyositis

YOSHINORI TANIGUCHI, TARO HORINO and YOSHIO TERADA

J Rheumatol 2009;36;1088-1089
http://www.jrheum.org/content/36/5/1088

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Cutaneous Amyloidosis Associated with Amyopathic Dermatomyositis

To the Editor:

Localized cutaneous amyloidoses can be divided into primary cutaneous amyloidosis and secondary cutaneous amyloidosis. Primary cutaneous amyloidosis is defined as deposition of amyloid in the skin in the absence of systemic involvement. Secondary cutaneous amyloidosis is associated with secondary amyloid deposition and is accompanied by skin neoplasms such as seborrheic keratosis, Bowen’s disease, basal cell carcinoma, porokeratosis, and trichoepithelioma. The cutaneous amyloid, so-called “amyloid-K,” is reported to be derived from cytokeratin1-3. We describe a case of amyopathic dermatomyositis (ADM) associated with cutaneous amyloidosis.

A 61-year-old woman with dyspnea and general fatigue was referred to our hospital. Two weeks before, she had developed fatigue and dyspnea. On admission, examination showed Raynaud’s phenomenon, Gottron’s sign, and periungual erythema (Figure 1), and poikiloderma on the trunk, without myalgia or muscle weakness. Skin biopsy of the right fourth finger showed positive staining with hematoxylin-eosin (Figure 2A; arrow) and positive staining with congo red in the papillary dermis (Figure 2B), indicating cutaneous amyloidosis that developed into ADM. The congo red-positive area was confirmed by green birefringence. In addition, immunohistochemical staining of the amyloid deposited lesion resulted in positive staining with anti-amyloid P antibody (Figure 2C; arrow) and anti-cytokeratin 5 antibody (Figure 2D; arrow), but negative staining with anti-amyloid A antibody, anti-kappa-chain antibody, and anti-lambda-chain antibody (not shown). Laboratory findings showed normal peripheral blood cell count and normal myogenic enzyme level, such as CPK (45 IU/l) and myoglobin (33 ng/ml; normal < 98 ng/ml). ELISA assay for autoantibodies showed positive levels of anti Jo-1 antibody (193.5 U/ml; normal < 9 U/ml) and anti SSA/Ro antibody. KL-6, a lung fibrosis marker, was 700 U/ml. Serum amyloid A was normal. Chest computed tomography revealed interstitial pneumonia. She was diagnosed with ADM associated with interstitial pneumonia and cutaneous amyloidosis.

Intravenous methylprednisolone pulse therapy (500 mg daily for 3 days) was started, followed by oral prednisolone 40 mg daily. Intravenous cyclophosphamide 500 mg monthly was added. Three months after starting these therapies, her colors of Gottron’s sign and periungual erythema gradually reduced and had disappeared after 6 months.

It is uncommon that cutaneous amyloidosis occurs in patients with DM4-6. A search of the PubMed database identified only 3 cases of patients with DM associated with cutaneous amyloidosis4-6. Previous reports described that the duration from the onset of eruption to the diagnosis of cutaneous amyloidosis by skin biopsy was approximately 10 years4-6. In patients with DM, cutaneous amyloidosis might be based on chronic inflammation. In our case and in previous reports complications including interstitial pneumonia, Raynaud’s phenomenon, periungual erythema, and Gottron’s sign have occurred. Because of positive anti-cytokeratin 5 antibody staining, we suggest that in patients with DM the cutaneous amyloidosis might derive mainly from cytokeratin 5 of basal keratinocytes as well as Bowen’s disease, basal cell carcinoma, and actinic keratosis2-3.

In patients with DM, the association of cutaneous amyloidosis and DM might be more frequent than we thought. Thus, testing of patients with DM for cutaneous amyloid could be worthwhile.

YOSHINORI TANIGUCHI, MD; TARO HORINO, MD, PhD; and YOSHIO TERADA, MD, PhD, Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi, Japan. Address reprint requests to Dr. Y. Taniguchi, Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi 783-8505, Japan. E-mail: jm-yoshii@kochi-u.ac.jp

REFERENCES

J Rheumatol 2009;36:5; doi:10.3899/jrheum.081148

Figure 1. Macroscopic findings of the hands. A. Gottron’s sign was noted on the proximal interphalangeal joint. Periungual erythema and capillary loops in proximal nail-folds were also revealed.
Figure 2. Microscopic findings from the skin biopsy. Skin biopsy was performed on the proximal interphalangeal joint of the right fourth finger, which had Gottron’s sign. Amyloid deposits were proven in the stratum papillare. A. Skin biopsy of the right fourth finger showed positive H&E staining. B. Positive staining with Congo red. C. Positive staining with anti-amyloid P antibody. D. Positive staining with anti-cytokeratin 5 antibody. (All original magnification ×400.)